Esculentoside A Alleviates Intestinal Dysmotility in Ulcerative Colitis by Regulating H₂S/CSE and NO/nNOS Systems

Figure 1

The therapeutic effects of Esculentoside A on dextran sulfate sodium (DSS)-induced ulcerative colitis (UC). (a) The number of rat bowel movements in the sham, model, Esculentoside A (EsA)-10, and EsA-20 groups. (b) The body weight of rats in the sham, model, EsA-10, and EsA-20 groups. (c) The length of carbon powder propulsion in the sham, model, EsA-10, and EsA-20 groups in the carbon powder propulsion experiment. (d) Hematoxylin and eosin staining in the sham, model, EsA-10, and EsA-20 groups. (e) The levels of TNF-α and IL-6 in the serum samples of the sham, model, EsA-10, and EsA-20 groups. , , and vs. model group by one-way ANOVA followed by Tukey’s post hoc test (n = 3).

(a)

(b)

(c)

(d)

(e)